Lou Gehrig's Disease or Amyotrophic Lateral Sclerosis (ALS) is a neurological disorder characterized by progressive degeneration of motor neuron cells in the spinal cord and brain, which ultimately results in paralysis and death. The disease takes its less-scientific name from Lou Gehrig, a baseball player with the New York Yankees in the late 1920s and 1930s, who was forced to retire in 1939 as a result of the loss of motor control caused by the disease.
In 1991, a team of researchers linked familial ALS to chromosome 21. Two years later, the SOD1 gene was identified as being associated with many cases of familial ALS. The enzyme coded for by SOD1 carries out a very important function in cells: it removes dangerous superoxide radicals by converting them into non-harmful substances. Defects in the action of this enzyme mean that the superoxide radicals attack cells from the inside, causing their death. Several different mutations in this enzyme all result in ALS, making the exact molecular cause of the disease difficult to ascertain.
Recent research has suggested that treatment with drugs called antioxidants may benefit ALS patients. However, since the molecular genetics of the disease are still unclear, a significant amount of research is still required to design other promising treatments for ALS.
A study by researchers at the University of California, San Diego School of Medicine shows there is increasing evidence that high rates of illness in Persian Gulf War Veterans can be explained, in part, by exposure to certain chemicals, including pesticides and nerve agents.
Scientists at Washington University School of Medicine in St. Louis have linked a mutation in a gene known as TDP-43 to an inherited form of amyotrophic lateral sclerosis (ALS), the neurodegenerative condition often called Lou Gehrig's disease.
In what the researchers say could be promising news in the quest to find a therapy to slow the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, scientists at the University of California, San Diego (UCSD) School of Medicine have shown that targeting neuronal support cells called astrocytes sharply slows disease progression in mice.
Discovery of an unexpected protein-protein interaction has led University of Iowa scientists and colleagues to identify a drug that slows the progression of Amyotrophic Lateral Sclerosis (ALS) in mice and nearly doubles the animals' lifespan.
A baby's brain has a lot of work to do, growing more neurons and connections.
A research team from Wake Forest University School of Medicine is the first to show that injections of a protein normally found in human cells can increase lifespan and delay the onset of symptoms in mice with ALS (amyotrophic lateral sclerosis), or Lou Gehrig's disease.
Newly launched nerve cells in a growing embryo must chart their course to distant destinations, and many of the means they use to navigate have yet to surface.
Avicena Group, Inc. has announced that the United States Patent and Trademark Office (USPTO) has granted the Company U.S. Patent #7,285,573 for the use of the Company's proprietary drug candidates for the treatment of amyotrophic lateral sclerosis ("ALS" or "Lou Gehrig's Disease").
A diet rich in fish, omega-3 oils, fruits and vegetables may lower your risk of dementia and Alzheimer's disease, whereas consuming omega-6 rich oils could increase chances of developing memory problems, according to a study published in the November 13, 2007, issue of Neurology, the medical journal of the American Academy of Neurology.
Rosemary not only tastes good in culinary dishes such as Rosemary chicken and lamb, but scientists have now found it is also good for your brain.
Researchers in Rensselaer Polytechnic Institute's Social and Behavioral Research Lab (SBRL) are leading a study to investigate potential environmental, lifestyle, and medical variables that may contribute to the onset of Amyotrophic Lateral Sclerosis (ALS).
MIT researchers have developed a new algorithm to help create prosthetic devices that convert brain signals into action in patients who have been paralyzed or had limbs amputated.
People treated with the drug minocycline within six to 24 hours after a stroke had significantly fewer disabilities, according to a study published in the October 2, 2007, issue of Neurology®, the medical journal of the American Academy of Neurology.
Scientists have discovered a link between a mutated gene and a protein found in dead brain cells of people who suffer from a form of dementia and other neurological disorders.
The Spinal Muscular Atrophy Foundation and BG Medicine have announced a collaboration to discover plasma biomarkers of drug efficacy for spinal muscular atrophy (SMA), the leading genetic cause of mortality in infants and toddlers.
There is no known cure for amyotrophic lateral sclerosis (ALS), often known as Lou Gehrig disease and motor neuron disease.
A nanotechnology developed by a University at Buffalo professor has enabled researchers to identify a molecular signature common to both familial and sporadic cases of amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease.
UCLA scientists have found the first evidence that a specific form of estrogen can protect the brain from degeneration yet not increase the risk for estrogen-induced cancers of the breast and uterus.
In a study that demonstrates the promise of cell-based therapies for diseases that have proved intractable to modern medicine, a team of scientists from the University of Wisconsin-Madison has shown it is possible to rescue the dying neurons characteristic of amyotrophic lateral sclerosis (ALS), a fatal neuromuscular disorder also known as Lou Gehrig's disease.
A small tropical fish, the curiosity of a Geisinger research scientist and some college students have created the perfect storm of sorts in an attempt to find a cure for one of the world's most devastating neurological diseases.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.